<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02892071</url>
  </required_header>
  <id_info>
    <org_study_id>PRO15090113</org_study_id>
    <nct_id>NCT02892071</nct_id>
  </id_info>
  <brief_title>Tri-split Face Study of Skin Resurfacing Modalities for the Treatment of Melasma</brief_title>
  <official_title>Tri-split Face Study of Skin Resurfacing Modalities for the Treatment of Melasma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tri-split face study of skin resurfacing modalities for the treatment of melasma, comparing
      the medium depth trichloroacetic acid peel, CO2 laser and Qs-NdYag laser.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Melasma is an acquired chronic and relapsing hyperpigmentation disorder, with a significant
      negative impact on the quality of life of patients. Melasma is more common in patients with
      skin of color and has also been linked to chronic ultraviolet (UV) and heat exposure, family
      history and hormonal factors. There are several studies in the literature using various
      therapies for melasma, including sun protection, topical therapies, lasers and chemical
      peels. However, many of these studies vary greatly in their efficacies and side effect
      profiles, due to varying and undelineated pre and post-op procedure regimens. Side effects of
      post-inflammatory hyper and hypopigmentation and rebound are reported in these studies. The
      investigators would like to conduct a tri-split face study that compares a 22%
      trichloroacetic acid (TCA) deep medium peel with an ablative fractionated CO2 laser and more
      pigment selective Q-switched (Qs) Nd:YAG laser. To minimize possible post-procedure side
      effects and melasma rebound, the investigators will perform above treatments in conjunction
      with an optimal skincare regimen, starting 6 weeks before and continuing after the
      treatments. The investigators will perform the 22% TCA chemical peel, CO2 laser and Qs-Nd:YAG
      at 6 weeks after the start of the skincare regimen, and repeat treatments with Qs-Nd:YAG at
      weeks 8, 10, and 12. The investigators will assess participants using standardized photos in
      conjunction with UV imaging (Visia CR) at weeks 0, 6, 16, 20 and 24 (6 months), by measuring
      the modified melasma area and severity index (mMASI) scores and visual analog scale (VAS)
      scores as graded by participants as well as by blinded physicians based on photos and UV
      imaging.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>modified melasma area and severity index (mMASI) score</measure>
    <time_frame>6 months</time_frame>
    <description>score calculated by measuring darkness of pigment of melasma patch area</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>visual analog scale (VAS) assessment by physicians</measure>
    <time_frame>6 months</time_frame>
    <description>CR</description>
  </secondary_outcome>
  <other_outcome>
    <measure>participant satisfaction assessment</measure>
    <time_frame>6 months</time_frame>
    <description>Participants will score their satisfaction with improvement for each modality</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Melasma</condition>
  <arm_group>
    <arm_group_label>22% TCA peel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>22% trichloroacetic acid medium depth chemical peel applied to one of the three facial areas (based on random assignment- forehead, left cheek, right cheek)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CO2 laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CO2 ablative fractional laser resurfacing applied to one of the three facial areas (based on random assignment- forehead, left cheek, right cheek)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Qs-NdYAG laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Long pulsed Q-switched Nd:Yag laser will be applied to one of the three facial areas (based on random assignment- forehead, left cheek, right cheek), performed at 2-week intervals for six sessions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>22% TCA peel</intervention_name>
    <description>One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with one treatment with a 22% TCA Blue Peel, to achieve a level 2 frost (medium depth peel). Each treatment will take about 20 minutes. A 22% TCA concentration will be created by combining 5.5 mL of 30% TCA (from a purchased commercial bottle) with 2mL of blue dye (commercial), immediately before application.</description>
    <arm_group_label>22% TCA peel</arm_group_label>
    <other_name>medium depth chemical peel</other_name>
    <other_name>TCA peel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CO2 laser</intervention_name>
    <description>One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will receive one treatment with one pass of the fractionated ablative 10,600 nm CO2 (CO2RE Laser, Syneron) at Core 70 mJ, Ring 50mJ, 40% coverage, 1 pass, 8 mm square pattern. Each treatment will take about 20 minutes.</description>
    <arm_group_label>CO2 laser</arm_group_label>
    <other_name>CO2RE laser, ablative fractional laser</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Qs-NdYag laser</intervention_name>
    <description>Long pulsed Q-switched Nd:Yag laser. One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with Q-switched (Qs) 1064 Nd:YAG (Medlite C3; 6 mm spot size, collimated homogenous flat- top beam profile, energy fluence 2.0 J/cm2, 5Hz), with 5% coverage and 2 passes (or until mild erythema detected). Treatments will be performed at 2-week intervals for six sessions. Each treatment will take about 20 minutes.</description>
    <arm_group_label>Qs-NdYAG laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female participants

          -  20 to 60 years old

          -  participants with melasma on forehead and both cheeks

          -  participants who failed topical therapy for melasma

          -  participants who have never tried other therapies for melasma

        Exclusion Criteria:

          -  pregnancy

          -  lactation

          -  use of oral contraceptive (OCP) within 3 months of starting the study

          -  hormonal therapy within 3 months of starting the study

          -  hormonal intrauterine device (IUD) within 3 months of starting the study

          -  history of poor wound healing or abnormal scarring

          -  history of lip or face herpes simplex virus infections

          -  active facial skin infection

          -  history of connective tissue disorders (such as lupus or scleroderma)

          -  history of isotretinoin therapy within 6 months of starting the study

          -  history of chemical peels, dermabrasion, laser therapy or intense pulse light (IPL)
             within 6 months before enrollment into the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzan Obagi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kseniya Golubets, MD</last_name>
    <phone>724-940-7546</phone>
    <email>kseniya.golubets@gmail.com</email>
  </overall_contact>
  <results_reference>
    <citation>Moubasher AE, Youssef EM, Abou-Taleb DA. Q-switched Nd: YAG laser versus trichloroacetic acid peeling in the treatment of melasma among Egyptian patients. Dermatol Surg. 2014 Aug;40(8):874-82. doi: 10.1097/DSS.0000000000000065.</citation>
    <PMID>25068546</PMID>
  </results_reference>
  <results_reference>
    <citation>Trelles MA, Velez M, Gold MH. The treatment of melasma with topical creams alone, CO2 fractional ablative resurfacing alone, or a combination of the two: a comparative study. J Drugs Dermatol. 2010 Apr;9(4):315-22.</citation>
    <PMID>20514787</PMID>
  </results_reference>
  <results_reference>
    <citation>Jalaly NY, Valizadeh N, Barikbin B, Yousefi M. Low-power fractional COâ‚‚ laser versus low-fluence Q-switch 1,064 nm Nd:YAG laser for treatment of melasma: a randomized, controlled, split-face study. Am J Clin Dermatol. 2014 Aug;15(4):357-63. doi: 10.1007/s40257-014-0080-x.</citation>
    <PMID>24858737</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2016</study_first_submitted>
  <study_first_submitted_qc>September 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <last_update_submitted>September 7, 2016</last_update_submitted>
  <last_update_submitted_qc>September 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Suzan Obagi</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

